Paragen Bio
Advanced technology for halting autoimmune diseases's impact on healthy tissues and organs, empowering doctors to preserve and protect patient health
Advanced technology for halting autoimmune diseases's impact on healthy tissues and organs, empowering doctors to preserve and protect patient health
Paragen Bio is a biopharmaceutical startup with a mission to combat the impact of autoimmune diseases on healthy tissues and organs. Founded in 2018, the company has attracted notable attention from investors, securing a significant $6.00M in its last venture round investment on 14 August 2018. This round was backed by reputable investors such as AbbVie Ventures, OneVentures, and the Medical Research Commercialisation Fund (MRCF), showcasing the industry's confidence in Paragen Bio's advanced technology. The company's innovative solution offers a promising approach to managing autoimmune conditions by empowering physicians to prevent further deterioration and destruction of healthy tissues and organs. With a focus on biopharma, biotechnology, and life sciences, Paragen Bio is poised to make notable strides in the healthcare industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $6.00M | 3 |
-logo.jpg){kind=logo}
|
14 Aug 2018 |
No recent news or press coverage available for Paragen Bio.
-logo.jpg){kind=logo}
We care about your data, and we'd love to use cookies make your experience better.
